Phase 2 Kidney Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Children and young people aged 18 months to 17 years old
• People who have been diagnosed with Wilms tumor (a type of kidney cancer) that has come back or stopped responding to treatment, where the diagnosis was confirmed by a tissue sample at the time of first diagnosis
• People who have already received at least 2 rounds of chemotherapy (standard or high-dose), or at least 1 round in cases where the relapse is considered high risk and no curative treatment options remain (enrolment in the 1-line case must be confirmed by trial coordinators)
• People whose disease can be seen and measured on an MRI or CT scan
• People who are well enough to carry out most normal daily activities, as measured by standard performance scoring tools used for their age group (confirm with trial site)
• People who are able to take medication by mouth, through a tube placed through the nose into the stomach, or through an approved feeding tube into the stomach
• People whose blood counts meet the required levels — specifically, a sufficient number of infection-fighting cells (neutrophils) and blood clotting cells (platelets)
• People whose liver function test results are within an acceptable range, with some allowance if liver spread is present (confirm with trial site)
• People whose kidney function is within an acceptable range, based on blood tests or urine clearance measurements
• Females who could become pregnant must have a negative blood pregnancy test within 7 days before starting treatment
• People who are sexually active must agree to use reliable contraception starting 1 month before treatment, throughout the trial, and for 7 months after finishing treatment for females, or 6 months after for males
• People (or their parents or legal guardians) who have given written agreement to take part, in line with national guidelines
• People who are covered by the French Social Security system

Who may not be able to join:

• People who have had another type of cancer in the past 5 years
• People who have had chemotherapy or radiotherapy to the areas being measured in the trial within the past 3 weeks before joining
• People who have recently received a targeted therapy, depending on how long that specific medication stays active in the body (confirm with trial site)
• People who have had major surgery within the past 15 days before joining
• People who have significant ongoing heart, liver, lung, or kidney side effects from previous treatment (graded as moderate or above on a standard medical scale)
• People with severely reduced bone marrow function affecting blood cell production
• People with significant nerve damage affecting the hands or feet (graded as moderate or above)
• People with a known intolerance to fructose (a type of sugar)
• People with a chronic inflammatory bowel condition or a blockage in the intestines
• People diagnosed with the demyelinating form of a nerve condition called Charcot-Marie-Tooth disease
• People with a known active hepatitis infection, HIV, or any other infection that is not currently under control
• People with a known allergy or sensitivity to dacarbazine, isotretinoin, or any of the other trial medications or their ingredients
• People with high levels of fats in the blood (hyperlipidemia) or excess vitamin A in the body
• People who have received a live vaccine within 1 month before joining
• People who are pregnant or breastfeeding
• People who would be unable to attend the required medical follow-up appointments due to geographic, social, or personal circumstances

Important: Always verify eligibility with the trial site directly before applying.